Answers are grounded in this paper and cite their sources.
Cladribine tablets (CladT) were initially approved for use in people with highly active relapsing multiple sclerosis (RMS) in 2017. However, following review of the clinical development programme and subsequent long-term efficacy and safety data, the Medicines and Healthcare products Regulatory Agency granted a label expansion, in March 2024, to include patients with active RMS. Based on the research and our multidisciplinary experience, we recommend that healthcare professionals consider CladT in disease-modifying treatment (DMT) conversations with all patients who have active or highly active RMS. In our experience, CladT are well suited as a first-line therapy for newly diagnosed and treatment-naïve patients, for those who require an alternative to chronic, continuous immunosuppression, such as older patients with RMS and those with comorbidities. CladT are a valuable high-efficacy DMT with a dosing and monitoring schedule that is conducive to family planning, employment and increasing accessibility for those with barriers to frequent hospital visits.
No takes yet. Share an insight, caveat, or question.
Arun et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: